Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure
Jacob George(University of Dundee), Gad Keren(Assuta Medical Center), Shuki Patal(Tel Aviv Sourasky Medical Center), Arie Roth(Tel Aviv University), David S. Sheps(University of Florida), Dov Wexler
Cited by 129
Related Papers
Mood Disorders in the Medically Ill: Scientific Review and Recommendations
|Biological Psychiatry|2005|1.1k
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
|Journal of the American College of Cardiology|2000|731
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
|Journal of the American College of Cardiology|2001|646
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504